At a glance
ClinicalIndex Comparison Record- ✓Histologically confirmed visual pathway glioma not amenable to standard therapy or unresponsive to standard therapy
- ✓Evidence of tumor by MRI within 2 weeks prior to study entry
- ✓Tumor must be at least 5 mm in size
- ✓Age 6 months to 17 years
- ✕Brain stem tumors
- ✕Severe heart disease, uncontrolled hypertension, history of congestive heart failure, or cardiovascular conditions contraindicated by high sodium dosages
- ✕Severe lung disease
- ✕Renal insufficiency or history of renal conditions contraindicated by high sodium dosages
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Antineoplastons A10 and AS2-1 Infusions in Children With Visual Pathway Glioma
In Brief
A Phase 2 clinical trial evaluating Antineoplaston therapy (Atengenal + Astugenal) for Visual Pathway Glioma. Completed, enrolled 12 participants across 1 site.
Detailed Summary
RATIONALE: Current therapies for children with visual pathway gliomas, which are not amenable to or have not responded to standard therapy, provide limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of children with visual pathway gliomas, which are not amenable to or have not responded to standard therapy. PURPOSE: This study is being performed to determine the effects (good and bad) that Antineoplaston therapy has on children with visual pathway gliomas, which are not amenable to or have not responded to standard therapy.
Study Details
Timeline
Interventions
Children with a visual pathway glioma, which is not amenable to standard therapy or has not responded to standard therapy, will receive Antineoplaston therapy (Atengenal + Astugenal).